Project description
Self-testing for chronic diseases
A combination of longer life expectancies and unhealthy lifestyles has resulted in increased numbers of people with multiple chronic conditions, such as diabetes, cholesterol, cardiovascular and kidney disease. Point-of-care testing (PoCT) technologies provide excellent solutions for home self-testing and management. However, the existing PoCT technologies on the market are still very complex and too expensive. The EU-funded PoCMICRUX project proposes an innovative miniaturised, multi-analyte, handheld PoCT device for multiple chronic disease self-testing and management. The innovation is the first cost effective, simple (one drop of blood, no training or calibration required), fast and handheld PoCT device allowing patients to accurately self test simultaneously four biomarkers (glucose, cholesterol, creatinine and uric acid) for the clinical diagnosis of high-prevalence diseases.
Objective
Longer life expectancies and unhealthy lifestyle has dramatically increase the prevalence multiple chronic conditions. There are over 50 million of people with such cumulative chronic conditions in Europe and, together, they total more than €700 billion healthcare expenditure which account for over 70% of the EU health budget. Recent Point-of-Care Testing (PoCT) technologies provide remarkable tools for home self-testing and management but the currently PoC on the market are still so complex and too expensive to be afforded by average patients. With PoCMicruX we intend to overcome this barrier and finally provide patients the first low-cost multi-analyte handheld Point-of-Care device for multiple chronic disease self-testing and management. PoCMicruX is a combination of microfluidic and electrochemical sensor technologies. Based on an innovative design totally made of electronical components and where fluid can simply be handled by capillary action, we will offer the only cost-effective (€150), simple (one drop of blood, no training or calibration required), fast (<2 min), and handheld PoC device allowing patients to accurately self-test simultaneously four clinical validated biomarkers (glucose, cholesterol, creatinine and uric acid) for the clinical diagnostic (monitoring and prevention) of high prevalence diseases such as diabetes, cholesterol, cardiovascular and kidney diseases. MicruX Technologies is a highly innovative Spanish company that, from its foundation in 2008, has been at the forefront of developing miniaturized lab-on-chip technology and miniaturized monitoring instrumentation, being already involved in several EU projects. We have already succeeded in launching more than 30 models of products currently marketed in 40 countries. We expect from PoCMicruX commercialization to provide an accumulated turnover of €26.7 million by 2023, with 8.5 million profit (profitability ratio of 57%). We foresee to create 50 new jobs by 2023.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- engineering and technologyother engineering and technologiesmicrotechnologylab on a chip
- medical and health sciencesclinical medicineendocrinologydiabetes
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensors
- medical and health sciencesclinical medicinenephrologykidney diseases
You need to log in or register to use this function
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
33211 Gijon
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.